Introduction
============

Nasopharyngeal carcinoma (NPC) is a kind of common malignancy in South China and Southeast Asia [@B1]. Its etiology is related to Epstein-Barr (EB) virus infection, genetic susceptibility, interaction between various oncogenes and tumor suppressor genes, environment and living customs and so on [@B2]. Because of the low outpatient rate at its early stage, the majority of NPC patients of in-hospital have reached III and IV stage, with a 5-year survival rate of 50% to 60% [@B3]. Carcinoma-associated fibroblasts (CAFs) have been generally considered to be spindle fibroblast-like stromal cells with expression of α-smooth muscle actin (α-sma) [@B4]. As a major and important component of tumor matrices, CAFs play an important role in tumor development, and promote tumorigenesis, invasiveness and metastasis by stimulating angiogenesis [@B5]. Several studies have shown that CAFs can be used as important prognostic factors in a variety of tumors [@B6]-[@B8]. However, its clinical significance in the prognostic value of NPCs has rarely reported. In this study, the expression of α-sma protein in NPC tissues was detected by immunohistochemistry and the association of its expression with clinicopathological characteristics was analyzed in NPCs by statistical analysis.

Materials and Methods
=====================

Ethics statement
----------------

The study was approved by the Institute Research Medical Ethics Committee of Sun Yat-sen University. No informed consent (written or verbal) was obtained for use of retrospective tissue samples from the patients within this study, most of whom were deceased, since this was not deemed necessary by the Ethics Committee, who waived the need for consent. All samples were anonymised.

Patients and tissue specimens
-----------------------------

We collected paraffin samples from September 2002 to November 2004 in Department of Pathology, Sun Yat Sun University Cancer Center, the number of the pathological diagnosis of NPC, nasopharyngitis and Metastatic tissues of NPC were 85 cases, 32 cases, 12 cases, respectively. The NPC group contained 65 males (76.5%) and 20 females (23.5%), with a median age of 44 and a mean follow-up time of 90.8 months (the median follow-up time was 110 months). The diagnostic criterion of all cases in this study was based on the 2000 WHO criteria for tumor classification, and tumor staging was on the basis of UICC (International Union against Cancer) and the AJCC (American Joint Committee on Cancer).

Immunohistochemistry (IHC)
--------------------------

The immunohistochemical staining of α-Smooth muscle actin (α-sma) protein was done according to standard EnVision™ procedure. We sliced the paraffin blocks into 3-μm sections and dry sections in incubator at 60℃. After deparaffinized with xylene and rehydrated in a graded ethanol series, the slides were placed in boiled citric acid buffer for antigen retrieval. We incubated the sections with first antibody α-sma (Sigma, A5228, operative solution concentration 1:12000) at 37℃ for 50min. After immersed in 3 % hydrogen peroxide for 10 min to inhibit the endogenous peroxidase activity, the sections were incubated with secondary antibody (DAKO, K5007) at 37℃ for 30min. Then, the color reaction was developed by 3,3-diaminobenzidine(DAB) and the degree of color development was controlled under microscope. Finally, the sections were counterstained with hematoxylin, dehydrated in a graded ethanol series, cleared in xylene, and mounted with neutral gum. Positive and negative controls were set in the staining procedure.

IHC evaluation
--------------

Positive or negative fibroblasts were identified on the basis of α-sma expression. The positive expression of α-sma protein is brownish yellow or chocolate brown in cytoplasm. Selecting 4 typical visual field of tumor stroma in every slice by high-power field of the microscope, we counted the area of α-sma-positive fibroblasts (CAFs) and calculated CAFs density (dCAFs) =the positive staining area/tumor stromal area (%) of every visual field (vascular positive staining as internal control was not counted) [@B8]. CAFs density is the mean value of the 4 fields. With double-blind method, staining score analyses were done by two independent and experienced pathology doctors. A more experienced pathology doctor would reevaluate the conflicting results.

Statistical Analysis
--------------------

Statistical analysis was performed using SPSS20.0 and the cut-off value of expression level was defined as the median of clinical commonly usage [@B9].The difference of CAFs density between the NPC tissues, the nasopharyngitis tissues and the metastatic tissues of NPCs, the relevance between the density of CAFs and the clinicopathological parameters of NPC patients were both verified by Chi-square test. The survival analysis of NPC patients was evaluated by the Kaplan-Meier method with log-rank test. Multivariate analyses were performed using Cox proportional hazard model. All *P* values were reported by two-sided analyses and *P*\<0.05 stands for the statistical significance level.

Result
======

Differential expression of CAFs in NPC tissues, nasopharyngitis tissues and metastatic tissues of NPCs by immunohistochemistry
------------------------------------------------------------------------------------------------------------------------------

There are different expression situation for CAFs in these three kinds of tissue (Figure [1](#F1){ref-type="fig"}). A median of 10% were served as the cut-off value of the CAFs expression level. CAFs are analyzed in NPC tissues, nasopharyngitis tissues and metastatic tissues of NPCs, and the high density rate is 41.2% (35/85), 6.2% (2/32) and 83.3% (10/12) respectively. There are significant differences among them by Chi-square Test (*P*\<0.05) (Table [1](#T1){ref-type="table"}).

The relation between the expression level of CAFs in NPC tissues and clinical pathological parameters
-----------------------------------------------------------------------------------------------------

Chi-square Test shows that the density of CAFs is significantly correlated with relapse (*P*=0.023), and T stage (*P=*0.005). But no significant correlation with other clinical pathological parameters (Gender, age, lymph node metastasis, treatment modality, *P*\>0.05) was found. (Table [2](#T2){ref-type="table"})

The relationship between the expression of CAFs and prognosis of NPC patients
-----------------------------------------------------------------------------

The univariate analysis demonstrated that these factors including age (*P*=0.027), T stage (*P*=0.003), relapse (*P*=0.000) and density of CAFs (*P*=0.000) were inversely associated with the prognosis of NPC patients (Table [3](#T3){ref-type="table"}). We introduce above significant factors into COX regression model to carry out multivariate analysis. The result shows that age is not independent prognostic risk factors (*P*\>0.05), while the density of CAFs, T stage and relapse can be identified as independent prognostic factors (*P*\<0.05) for the prognosis of the NPC patients (Table [4](#T4){ref-type="table"}). Kaplan-Meier analysis demonstrated that the mean overall survival of patients with low CAFs density and patients with high CAFs density are 127.0 months and 86.8 months (*P*=0.000, Figure [2](#F2){ref-type="fig"}A). And revealed that the mean progression-free survival are respectively 130.1 months and 97.2 months (*P*=0.006, Figure [2](#F2){ref-type="fig"}B). Life table analysis showed that the 5 year survival of patients with low CAFs density and high CAFs density are respectively 90.0% (45/50) and 57.1% (20/35) (*P*=0.000).

Discussion
==========

α-sma, the subtype of α-actin genetically coded by ACTA2, is a member of the highly conserved actin family. It plays a key role in cell movement, structure and integrity. α-sma, reflecting the expression of CAFs in mesenchyme, is the most common marker of CAFs and does not express on normal nasopharyngitis epithelial cells or mesenchymal fibroblasts [@B10]. CAFs have been identified to be the most abundant cells in the tumor microenvironment [@B11]. CAFs is one of the major components of the epithelial-mesenchymal transition (EMT) [@B8] and may be associated with EMT of tumor cells and lymphogenesis of metastatic microenvironment [@B12]. EMT, which promotes the mesenchymal fibrosis and the tumor progressiveness [@B13], is a critical factor during invasion and metastases of cancer cells [@B14]. Raghu Kalluri et al, [@B15] showed that matrix microenvironment was vital to the tumorigenesis, development and metastases.

This study was initially to use the density of CAFs as an evaluation index for patient\'s prognosis in NPCs. Our results found the density of CAFs in NPC tissues was significantly higher than that in nasopharyngitis tissues. In addition, the density of CAFs in metastatic tissues of NPCs was also significantly higher than that of local region. Patients with high density of CAFs had worse overall survival than that with low density. The CAFs in mesenchyme of NPC tissues in this study has preliminarily revealed that its importance in tumorigenesis, tumor metastases and predicting the prognosis of NPC patients.

This research detected the density of CAFs in NPC tissues, nasopharyngitis tissues and metastatic tissues of NPCs by immunohistochemistry. The results showed that the rates of high density of CAFs in the three groups are 41.2%, 6.2% and 83.3% respectively, and a significantly statistical difference was displayed among them, indicating that CAFs have an important role in development and metastases of NPCs, which is consistent with the results of previous researches. CAFs is the major and important component of tumor stroma which plays an important role in the growth and development of epithelial tumor [@B16], [@B17] by stimulating angiogenesis, secreting soluble factors (eg, growth factors, inflammatory cytokines ) and reconstructing extracellular matrix (ECM) and tumor metabolites, adjust the motility and pluripotency [@B18], [@B19] of the tumor to make early-stage preparations for metastases.

We further revealed that the density of CAFs had a significant correlation with T stage in NPC tissues, and the mean overall survival for patients with low CAFs density is inversely longer than that of patients with high CAFs density. This result is in accordance with Yu feng Cheng\'s team\'s findings in their esophageal squamous cell carcinoma research which showed that the 5-year survival rate of groups with higher expression of α-SMA was significantly lower [@B20]. In addition, Susumu Saigusa\'s research on rectal cancer [@B21] and Ibrahim O. Bello\'s research on mobile tongue cancer [@B22] both proved that CAFs correlate with poor prognosis, and also are related to the tumor malignant degree, tumor growth and progressiveness. Similarly, some studies have showed that stromal CAFs are associated with a high risk of recurrence and worse prognosis in other solid cancers including colorectal and breast cancer [@B23], [@B24] Multivariate analysis in our research indicated that CAFs density was served as independent prognostic factor for NPCs. The similar conclusion was also reported for other epithelial tumors [@B20]. The evidences above revealed CAFs\' important role in the occurrence, development, metastasis and prognostic evaluation of NPCs. Moreover, targeting stromal CAFs inhibited the growth of cholangiocarcinoma and improved survival of host in an experimental study [@B25]. Therefore, an approach that targets CAFs could be a novel strategy for cancer therapies in the future. However, the molecular mechanism of CAFs in the progressiveness and metastases of NPCs remained unclear. Thus further researches on mechanism of molecular pathway would be a meaningful attempt.

In this study, we also found a rather curious phenomenon, that is, a small amount of NPC cells really expressed α-sma. This indicated some of the NPC cells could have achieved the characteristics of CAFs, suggesting a stronger metastatic ability has existed in these NPC cells, which is consistent with Hye Won Lee\'s team\'s research of lung cancer that is associated with EMT mechanism of tumor cells [@B26]. However, according to expression profile, generally α-sma only expressed itself in fibroblasts, smooth muscles and perivascular cells. Therefore, it is necessary for exploring how a-sma regulated the related molecular involving with EMT in the further study.

Undeniable, there are several limitations of this study. Firstly, the sample size of this study is not large enough. Our conclusion needs to be verified in future by a multi-institution investigation. Secondly, retrospective data requires validation by prospective multi-institution study. However, our data revealed that high density of CAFs was significantly associated with clinical outcomes of patients with NPCs, and thus indicated high density of CAFs as a high risk factor for the development of the patients with NPCs.
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###### 

The expression of α-sma in the NPCs, Nasopharyngitis and Metastatic tissues of NPCs

  Variable                     CAFs                             
  ---------------------------- ------ ------------ ------------ -----------
  Tissue type                                                   **0.000**
  NPCs                         85     50 (58.8%)   35(41.2%)    
  Nasopharyngitis              32     30 (93.8%)   2 (6.2%)     
  Metastatic tissues of NPCs   12     2 (16.7%)    10 (83.3%)   

^a^ Chi-square test.

###### 

Correlation of CAFs with patients\' clinicopathological features in nasopharyngeal carcinomas

  Variable                CAFs                             
  ----------------------- ------ ------------ ------------ -----------
  Age (years) ^b^                                          0.054
  ≤ 45.4                  47     32 (68.1%)   15 (31.9%)   
  \> 45.4                 38     18 (47.4%)   20 (52.6%)   
  Gender                                                   0.521
  Male                    65     37 (56.9%)   28 (43.1%)   
  Female                  20     13 (65.0%)   7 (35.0%)    
  T stage                                                  **0.005**
  T1 And T2               32     25 (78.1%)   7 (21.9%)    
  T3 And T4               53     25 (47.2%)   28 (52.8%)   
  Lymph node                                               0.270
  N0                      17     12 (70.6%)   5 (29.4%)    
  N1,N2 And N3            68     38 (55.9%)   30 (44.1%)   
  Therapy ^c^                                              0.793
  Therapy1 And Therapy2   62     37 (59.7%)   25 (40.3%)   
  Therapy3 And Therapy4   23     13 (56.5%)   10 (43.5%)   
  Relapse                                                  **0.023**
  Yes                     11     3 (27.3%)    8 (72.7%)    
  No                      74     47 (63.5%)   27 (36.5%)   

^a^Chi-square test, ^b^Mean age, ^c^Therapy: Therapy 1 is Radiotherapy; Therapy 2 is Chemoradiotherapy; Therapy 3 is Inductive treatment and Radiotherapy; Therapy 4 is Inductive treatment and chemoradiotherapy.

###### 

Univariate analysis of clinicopathologic variables in 85 patients with nasopharyngeal carcinomas (log-rank test)

  --------------------------------------------------------------------------------------------------
  Variable                All cases   Mean survival(months)   Median survival(months)   *P* value
  ----------------------- ----------- ----------------------- ------------------------- ------------
  Age (years) ^a^                                                                       **0.027**

  ≤ 45.4                  47          122.0                   N                         

  \> 45.4                 38          101.4                                             

  Gender                                                                                0.371

  Male                    65          112.1                   N                         

  Female                  20          118.0                                             

  T stage                                                                               **0.003**

  T1 And T2               32          128.6                   N                         

  T3 And T4               53          103.3                   121.0                     

  Lymph node                                                                            0.217

  N0                      17          125.5                   N                         

  N1,N2 And N3            68          110.5                                             

  Therapy ^b^                                                                           0.475

  Therapy1 And Therapy2   62          111.4                   N                         

  Therapy3 And Therapy4   23          119.4                                             

  Relapse                                                                               **0.000**

  Yes                     11          78.7                    67.0                      

  No                      74          119.0                   N                         

  CAFs\                   50\         127.0\                  N\                        **0.000**\
  Low density\            35          86.8                    108.0                     \
  High density                                                                          
  --------------------------------------------------------------------------------------------------

^a^ Mean age; ^b^ Therapy: Therapy 1 is Radiotherapy; Therapy 2 is Chemoradiotherapy; Therapy 3 is Inductive treatment and Radiotherapy; Therapy 4 is Inductive treatment and Chemoradiotherapy.

###### 

COX multivariate analysis of prognostic factors on overall survival

  Variable                               Hazards ratio   95% CI         *P* value
  -------------------------------------- --------------- -------------- -----------
  Age (years) ^a^ (\<=45.4 vs. \>45.4)   2.083           0.861-5.043    0.104
  T stage (T1-T2 vs. T3-T4)              4.656           1.276-16.991   **0.020**
  Relapse (No vs. Yes)                   4.760           1.698-13.342   **0.003**
  CAFs density (Low vs. High)            3.108           1.104-8.753    **0.032**

^a^ Mean age.
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